Mizuho Markets Cayman LP Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Mizuho Markets Cayman LP bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 24,958 shares of the biopharmaceutical company’s stock, valued at approximately $9,925,000. Alnylam Pharmaceuticals comprises 0.5% of Mizuho Markets Cayman LP’s portfolio, making the stock its 27th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Capital Research Global Investors lifted its position in Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. Groupama Asset Managment lifted its position in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Orbis Allan Gray Ltd lifted its position in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $297.45 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The firm’s 50-day simple moving average is $311.16 and its 200-day simple moving average is $359.49. Alnylam Pharmaceuticals, Inc. has a twelve month low of $284.19 and a twelve month high of $495.55. The firm has a market cap of $39.71 billion, a P/E ratio of 81.27 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned ($0.44) EPS. The firm’s revenue was up 96.4% on a year-over-year basis. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total transaction of $567,538.50. Following the sale, the executive vice president owned 23,406 shares in the company, valued at approximately $7,483,834.44. This trade represents a 7.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 21,255 shares of company stock worth $6,930,337 in the last 90 days. 0.86% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALNY. Jefferies Financial Group restated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Chardan Capital restated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.